Literature DB >> 3045826

Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.

S Chouaib1, J Bertoglio, J Y Blay, C Marchiol-Fournigault, D Fradelizi.   

Abstract

Large granular lymphocytes (LGL) can be activated by interleukin 2 (IL-2) to lymphokine-activated killers (LAK). The effect of tumor necrosis factor (TNF) on LAK generation was investigated. TNF was found to act synergistically with low concentrations of IL-2 (0.10-0.25 ng/ml), which were ineffective by themselves in inducing LAK activity, to promote the differentiation of LGL into non-major histocompatibility complex-restricted killers. When IL-2 was used at concentrations optimal for LAK generation, TNF did not further enhance this phenomenon. Specific binding of 125I-labeled TNF to LGL was increased by IL-2 stimulation. Scatchard analysis of TNF binding revealed the existence of two classes of binding sites with markedly different affinities (Kd values of 57 and 600 pM). We also demonstrated that the IL-2/TNF synergistic induction of LAK activity did not involve either IL-1 or interferon-gamma. This IL-2/TNF synergistic effect was blocked by anti-Tac antibodies. Immunofluorescence analysis revealed that IL-2/TNF selectively up-regulated Tac antigen expression on LAK precursors. Our results suggest a functional interaction between IL-2 and TNF on LAK precursors, which results in a reduction of the IL-2 concentration required for differentiation of LGL into LAK killers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3045826      PMCID: PMC282081          DOI: 10.1073/pnas.85.18.6875

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions.

Authors:  M Sharon; R D Klausner; B R Cullen; R Chizzonite; W J Leonard
Journal:  Science       Date:  1986-11-14       Impact factor: 47.728

3.  Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6.

Authors:  A Harel-Bellan; A Quillet; C Marchiol; R DeMars; T Tursz; D Fradelizi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Identity of differentiation inducing factor and tumour necrosis factor.

Authors:  K Takeda; S Iwamoto; H Sugimoto; T Takuma; N Kawatani; M Noda; A Masaki; H Morise; H Arimura; K Konno
Journal:  Nature       Date:  1986 Sep 25-Oct 1       Impact factor: 49.962

5.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

Authors:  B J Sugarman; B B Aggarwal; P E Hass; I S Figari; M A Palladino; H M Shepard
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

6.  Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.

Authors:  K Pfizenmaier; P Scheurich; C Schlüter; M Krönke
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

7.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

8.  Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.

Authors:  K Teshigawara; H M Wang; K Kato; K A Smith
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

9.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

10.  Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.

Authors:  J Vilcek; V J Palombella; D Henriksen-DeStefano; C Swenson; R Feinman; M Hirai; M Tsujimoto
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  22 in total

1.  Effects of tumor-necrosis-factor-activated neutrophils on tumor cell survival.

Authors:  H Shau
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Development of a serum-free medium for a human immortalized fibroblast cell line (KMST-6/TNF) producing tumor necrosis factor-alpha (TNF-alpha) and growth inhibitory effects of its conditioned medium on malignant cells in culture.

Authors:  S H Oh; M Miyazaki; M Namba
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

4.  Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha.

Authors:  D B Dubravec; D R Spriggs; J A Mannick; M L Rodrick
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha.

Authors:  B Meier; H H Radeke; S Selle; M Younes; H Sies; K Resch; G G Habermehl
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

6.  7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.

Authors:  B L Pope; J Sigindere; E Chourmouzis; P MacIntyre; M G Goodman
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

7.  Induction of lymphokine-activated killer activity in mice by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G V Dedoussis; N G Papadopoulos; O Tsolas; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

8.  IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.

Authors:  C Bello-Fernandez; P Oblakowski; A Meager; A S Duncombe; D M Rill; A V Hoffbrand; M K Brenner
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

9.  Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

Authors:  K Yoneda; T Osaki; T Yamamoto; E Ueta
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

10.  Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo.

Authors:  S M Dubinett; L Patrone; J Tobias; A J Cochran; D R Wen; W H McBride
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.